<div class="container">

<table style="width: 100%;"><tr>
<td>ssim3p3</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Simulation of n dose-escalation study with the 3+3 design
</h2>

<h3>Description</h3>

<p>The ssim3p3 function simulates n dose-escalation study with the 3+3 design and provides summarized results.
</p>


<h3>Usage</h3>

<pre><code class="language-R">ssim3p3(truerate, n, r = 2, seed = NULL)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>truerate</code></td>
<td>
<p>A nlevel-length vector of true rates for the DLTs.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n</code></td>
<td>
<p>Number of studies to simulate.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>r</code></td>
<td>
<p>Integer, number of digits for percentages in output.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>seed</code></td>
<td>
<p>If not empty, the seed to use for random generation.
</p>
</td>
</tr>
</table>
<h3>Value</h3>

<table>
<tr style="vertical-align: top;">
<td><code>data</code></td>
<td>
<p>Summarized result in a "np1" view.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>norecommendation</code></td>
<td>
<p>Percentage of studies with no recommendation for the MTD (in case of the first level is considered as toxic).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>mean.npt</code></td>
<td>
<p>Mean number of enrolled patients.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>mean.ndlt</code></td>
<td>
<p>Mean number of observed DLTs.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>mean.lastdose</code></td>
<td>
<p>Mean last experimented dose level.</p>
</td>
</tr>
</table>
<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code>troisPtrois</code>, <code>sim3p3</code>
</p>


<h3>Examples</h3>

<pre><code class="language-R">ssim3p3(c(0.1,0.2,0.25,0.35),100)
</code></pre>


</div>